3 Rock Solid Dividend That Pay You Every Month
Three blue-chip dividend stocks, each on a different quarterly payment schedule, can fill every month of the year with income, but each one carries a distinct risk that could derail the whole ladder.
Building a monthly income stream from quarterly dividend payers requires just a little scheduling. Three blue chips, staggered on different quarterly calendars, can deliver a paycheck in every month of the year. Altria (NYSE:MO | MO Price Prediction) pays in January, April, July, and October. AbbVie (NYSE:ABBV) pays in February, May, August, and November. Chevron (NYSE:CVX) pays in March, June, September, and December. Together, these three tickers cover all 12 months while offering attractive dividends along the way.
Here is what each leg of the ladder actually pays, how it has grown, and where the risks sit.
Altria: January, April, July, October
Altria just paid investors $1.06 per share on July 10, 2026, holding the level from the two prior quarters. The tobacco maker trades at $68.08 and carries a dividend yield of 6.19%, the highest of the three. Trailing 12-month payouts total $4.24, with the annualized forward at the same level.
The growth track record is proven. Altria has stepped the payout higher every year in this dataset, from $0.86 in 2020 to the current $1.06. Fundamentals are cooperating: management guided 2026 adjusted EPS to $5.56 to $5.72, and the Q1 earnings report of $1.32 beat the $1.25 estimate on revenue of $5.43 billion. Shares are up 23.72% year to date.
The risk to watch is regulatory and legal. Several third-party securities investigation notices have circulated in recent weeks, including a August 24, 2026 notice from Schall, Brown & Schwartz. These are not company announcements, and they do not change the dividend. They do reinforce why Altria trades at a forward multiple of just 12x.
AbbVie: February, May, August, November
AbbVie just paid investors $1.73 per share on August 14, 2026, the third payment at that level after a step up from $1.64. The trailing 12-month total sits at $6.83, with the annualized forward at $6.92. At the recent $259.76 quote, the yield is 2.58%.
The cash-flow story is the point. On the Q2 call, CFO Scott Reents told analysts AbbVie has “strong cash flows, balance sheet, and business outlook” and “substantial financial flexibility to pursue additional innovative business development.” Skyrizi hit $5.5 billion in the quarter, up 24% operationally, and Rinvoq cleared $2.5 billion, up 23.7%. Management lifted full-year adjusted EPS guidance to $13.87 to $14.07.
Here’s the catch: the reported profitability was depressed by acquisition accounting, which pushes the trailing PE to 75x even though forward PE is 19x. Investors that are seriously relying on the payout should track leverage after the Apogee deal closes. Management committed to a net leverage ratio of two times within two to three years following the deal close. Shares have run 30.1% over the past year.
Chevron: March, June, September, December
Chevron declared its latest $1.78 quarterly payout on July 29, 2026, with a record date of August 19, 2026 and payment on September 10, 2026. That marks a step up from $1.71 in 2025 and $1.63 in 2024. Trailing 12-month payouts total $7.05, with the annualized forward at $7.12. Yield sits at 3.44%.
The Q2 report gave dividend investors what they wanted: adjusted earnings of $12 billion, or $6.06 per share, adjusted free cash flow of $15.4 billion, and debt reduction of more than $8 billion in the quarter. Net debt to cash flow from operations closed at 0.6 times. CEO Mike Wirth told the call, “Consistent with our longstanding financial priorities, we intend to reward our shareholders today tomorrow and long into the future.” The Hess assets are generating strong free cash flow, which has been roughly double the incremental dividends and accretive to shareholders on a per share basis.
Chevron shares are up 35.01% year to date and 32.22% over the past year. Forward PE is 13x.
Putting the Ladder Together
Equal-weighted, these three names blend to a yield around 4%, with concentrated exposures worth noting: tobacco regulation for Altria, biosimilar and pipeline execution for AbbVie, and commodity prices for Chevron. That mix is the reason the ladder works. When crude cracks widen, Chevron benefits. When defensive consumer names catch a bid, Altria carries the load. AbbVie sits in the middle as a healthcare hedge with a growing payout. If a three-stock stagger still feels too rough, there is another route: funds and stocks that cut a check every 30 days on their own, seven of which we lined up in a free report here: The 7 Monthly Dividend Stocks That Pay You Every 30 Days. The next event on the calendar: Chevron pays on September 10, 2026. Keep an eye on the stock and the ex-date if you want to be included in the next round.
Contact [email protected] for any questions or corrections.
Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics. Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications. A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.
